CanAssist Breast

The most meaningful validation comes from clinicians themselves.

In his LinkedIn post, Dr.M V Chandrakanth offers an unbiased comparison of prognostic approaches in HR+ HER2- early breast cancer: insights that help guide better decisions.

#mvonco #breastcancer #oncology #meded | Dr.M V Chandrakanth Oncotype DX vs CanAssist Breast Two different approaches to the same clinical question: 👉 Who really needs chemotherapy? 🔬 Oncotype DX → genomic test ✔ Predicts chemo benefit + recurrence risk 🧪 CanAssist → proteomic test ✔ Estimates recurrence risk using biology + clinical factors ...

CanAssist Breast Test latest data to be featured at the San Antonio Breast Cancer Symposium 2025.

Stay tuned for more updates.

hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag

Spreading light, hope, and health this Diwali — because every spark inspires strength. 💖🪔

May the spirit of Dussehra inspire courage, hope, and strength in every battle.